# MMR CDC recommendations- tabular CDSS rules (optimal)

Updated on 2024-08-09

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | **MedIndication1** | **MedIndication2** | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | **Note-display** | **Note** |
| **MMR** |  |  |  |  | **Y/N** | **Dose** | **Adm date** |  |  |  |  |  |  |  |  |  |
| **Regular and catch-up without prior vaccination records** | | | | | | | | | | | | | | | | |
|  | 1 | < 12 mon |  |  | N + No MMRV |  |  |  |  |  | Schedule 1st dose 12-15 mon of age | Schedule 2nd dose 4-6 yr of age |  |  |  |  |
|  | 2 | >= 12 months | AND <= 47 mon |  | N + No MMRV |  |  |  |  |  | Admin 1 dose | Schedule 2nd dose 4-6 yr of age |  |  | MMRV only by preference, 3 mon apart |  |
|  | 3 | > 47 mon | AND <=18 yr |  | N + No MMRV |  |  |  |  |  | Admin 1 dose | Schedule 2nd dose > = 4 wk of 1st dose |  |  |  |  |
| **Regular and catch-up with prior vaccination records** | | | | | | | | | | | | | | | | |
|  | 4 | > 12 mon | AND < 4 yr |  | Y (MMR or MMRV) | 1 | 12-15 mon of age |  |  |  | Schedule 2nd dose 4-6 yr of age |  |  |  |  |  |
|  | 5 | > 12 mon | AND < 4 yr |  | Y (MMR) | 1 | (> 15 mon OR < 12 mon of age) AND >= 4 wk 1st dose |  |  |  | Admin 2nd dose |  |  |  |  |  |
|  | 6 | > 12 mon | AND < 4 yr |  | Y (MMR) | 1 | (> 15 OR < 12 mon of age) AND < 4 wk 1st dose |  |  |  | Schedule 2nd dose >= 4 wk of 1st dose |  |  |  |  |  |
|  | 7 | >= 4 yr | AND <= 18 yr |  | Y (MMR) | 1 | >= 4 wk |  |  |  | Admin 2nd dose |  |  |  |  |  |
|  | 8 | >= 4 yr | AND <= 18 yr |  | Y (MMR) | 1 | < 4 wk |  |  |  | Schedule 2nd dose > =4 wk of 1st dose |  |  |  |  |  |
| **With medical indications, contraindication, precaution** | | | | | | | | | | | | | | | | |
|  | 9 |  |  |  | N + No MMRV |  |  | Pregnant |  |  | Schedule/admin 1st dose ***after pregnancy*** | Schedule 2nd dose >= 4 wk of 1st dose |  |  |  |  |
|  | 10 |  |  |  | Y (MMR) | 1 |  | Pregnant |  |  | Schedule/admin 2nd dose ***after pregnancy***, >= 4 wk of 1st dose |  |  |  |  |  |
|  | 11 |  |  |  |  |  |  | Severe immunocompromised | Or severe immunodeficiency (e.g., hematologic and solid tumors, recipient of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy) |  | **DO NOT administer or schedule** |  |  |  |  | Contradictions to MMR |
|  | 12 |  |  |  |  |  |  | HIV severe immunocompromised, HIV positive AND < 15% CD4 counts | OR HIV severe immunocompromised, HIV positive AND total CD4 counts < 200/mm3 |  | **DO NOT administer or schedule** |  |  |  |  | Contradictions to MMR |
|  | 13 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or a vaccine component |  |  | **DO NOT administer or schedule** |  |  |  |  | Contradictions to MMR |
|  | 14 |  |  |  |  |  |  | Family history of altered immunocompetence, unless verified or by lab testing as immunocompetent |  |  | **DO NOT administer or schedule** |  |  |  |  | Contradictions to MMR |
|  | 15 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
|  | 16 |  |  |  |  |  |  | Recent (<=11 mon) recipient of antibody-containing blood product |  |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  | Please check the specific product for a specific interval | Precaution |
|  | 17 |  |  |  |  |  |  | History of thrombocytopenia | OR history of thrombocytopenic purpura |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
|  | 18 |  |  |  |  |  |  | Need for tuberculin skin testing | OR need for interferon-gamma release assay (IGRA) testing |  | Only admin if benefits outweigh risks for an adverse reaction |  |  |  |  | Precaution |
| **Special conditions** | | | | | | | | | | | | | | | | |
|  | 19 | >= 6 mon | AND <= 11 mon | International travel | N + No MMRV |  |  |  |  |  | Administer 1st dose before departure | Schedule revaccination, 1st dose at 12 mon age (high-risk area) or 12- 15 mon age | Schedule 2nd dose >= 4 weeks of 1st dose (revaccination) |  |  |  |
|  | 20 | > 12 mon |  | International travel | N + No MMRV |  |  |  |  |  | Administer 1st dose | Schedule 2nd dose >= 4 wk of 1st dose ***before departure*** |  |  |  |  |
| **MMRV** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Upon caregivers’ or parents’ preference** | | | | | | | | | | | | | | | | |
|  | 21 | >= 12 mon | <= 47 Mon |  | N + No MMRV |  |  |  |  |  | Admin 1 st dose **only if caregiver requests** | Schedule 2nd dose > = 3 mon interval |  |  |  |  |
|  | 22 | >= 12 mon | <= 47 Mon |  | Y | 1 | >= 3 mon 1st dose |  |  |  | Admin 2nd dose |  |  |  |  |  |
|  | 23 | >= 12 mon | <= 47 Mon |  | Y | 1 | < 3 mon 1st dose |  |  |  | Schedule 2nd dose > =3 mon of 1st dose |  |  |  |  |  |
| **Regular** | | | | | | | | | | | | | | | | |
|  | 24 | >47 mon | AND <= 12 yr |  | N + No MMRV |  |  |  |  |  | Admin 1 st dose | Schedule 2nd dose > = 3 mon AND P <= 12 yr |  |  |  |  |
|  | 25 | <= 12 yr |  |  | Y | 1 | >= 3 mon 1st dose |  |  |  | Admin 2nd dose |  |  |  |  |  |
|  | 26 | <= 12 yr |  |  | Y | 1 | < 3 mon 1st dose |  |  |  | Schedule 2nd dose > =3 mon of 1st dose AND P <= 12 yr |  |  |  |  |  |
|  | 27 | > 12 yr |  |  | Y | 1 |  |  |  |  | **DO NOT administer or schedule** |  |  |  | Maximal age MMRV: 12 yr |  |
|  | 28 | <12 yrs |  |  | Y | 1 |  | Pregnant |  |  | Schedule/admin 2nd dose after pregnancy, >= 3 mon of 1st dose AND P <= 12 yr |  |  |  |  |  |